Cargando…

A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform

Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Haerkens, Freek, Kikken, Charlotte, Kirkels, Laurens, van Amstel, Monique, Wouters, Willemijn, van Doornmalen, Els, Francke, Christof, Hughes, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399480/
https://www.ncbi.nlm.nih.gov/pubmed/36033279
http://dx.doi.org/10.1016/j.heliyon.2022.e10108
_version_ 1784772531100581888
author Haerkens, Freek
Kikken, Charlotte
Kirkels, Laurens
van Amstel, Monique
Wouters, Willemijn
van Doornmalen, Els
Francke, Christof
Hughes, Samantha
author_facet Haerkens, Freek
Kikken, Charlotte
Kirkels, Laurens
van Amstel, Monique
Wouters, Willemijn
van Doornmalen, Els
Francke, Christof
Hughes, Samantha
author_sort Haerkens, Freek
collection PubMed
description Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disease, so that in vitro results are not easily translatable to clinical situations. A promising way to circumnavigate these issues is to reposition already approved drugs for new treatments, enabling a more streamlined drug discovery process due to the availability of pre-existing pharmacological and toxicological datasets. Chemical libraries, such as the Prestwick Chemical Library of 1200 FDA approved drugs, are available for this purpose. We have developed a simple semi-automated whole-organism approach to screening the Prestwick Chemical Library for those compounds which reduce fat content using the model organism Caenorhabditis elegans. Our whole-organism approach to high-throughput screening identified 9 “lead” compounds that reduced fat within 2 weeks in the model. Further screening and analysis provided 4 “hit” compounds (Midodrine, Vinpocetine, Fenoprofen and Lamivudine) that showed significant promise as drugs to reduce fat levels. The effects of these candidates were found to further reduce fat content in nematodes where an nhr-49/PPAR mutation resulted in “overweight” worms. Upon unblinding the “hit” compounds, they were found to have recently been shown to have anti-obesity effects in mammalian models too. In developing a whole-animal chemical screen to identify pharmacological agents as potential anti-obesity compounds, we demonstrate how chemical libraries can be rapidly and relatively cheaply profiled for active hits. Using the nematode Caenorhabditis elegans thus enables drugs to be assessed for applicability in humans and provides a new incentive to explore drug repurposing as a feasible and efficient way to identify new anti-obesity compounds.
format Online
Article
Text
id pubmed-9399480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93994802022-08-25 A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform Haerkens, Freek Kikken, Charlotte Kirkels, Laurens van Amstel, Monique Wouters, Willemijn van Doornmalen, Els Francke, Christof Hughes, Samantha Heliyon Research Article Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disease, so that in vitro results are not easily translatable to clinical situations. A promising way to circumnavigate these issues is to reposition already approved drugs for new treatments, enabling a more streamlined drug discovery process due to the availability of pre-existing pharmacological and toxicological datasets. Chemical libraries, such as the Prestwick Chemical Library of 1200 FDA approved drugs, are available for this purpose. We have developed a simple semi-automated whole-organism approach to screening the Prestwick Chemical Library for those compounds which reduce fat content using the model organism Caenorhabditis elegans. Our whole-organism approach to high-throughput screening identified 9 “lead” compounds that reduced fat within 2 weeks in the model. Further screening and analysis provided 4 “hit” compounds (Midodrine, Vinpocetine, Fenoprofen and Lamivudine) that showed significant promise as drugs to reduce fat levels. The effects of these candidates were found to further reduce fat content in nematodes where an nhr-49/PPAR mutation resulted in “overweight” worms. Upon unblinding the “hit” compounds, they were found to have recently been shown to have anti-obesity effects in mammalian models too. In developing a whole-animal chemical screen to identify pharmacological agents as potential anti-obesity compounds, we demonstrate how chemical libraries can be rapidly and relatively cheaply profiled for active hits. Using the nematode Caenorhabditis elegans thus enables drugs to be assessed for applicability in humans and provides a new incentive to explore drug repurposing as a feasible and efficient way to identify new anti-obesity compounds. Elsevier 2022-08-11 /pmc/articles/PMC9399480/ /pubmed/36033279 http://dx.doi.org/10.1016/j.heliyon.2022.e10108 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Haerkens, Freek
Kikken, Charlotte
Kirkels, Laurens
van Amstel, Monique
Wouters, Willemijn
van Doornmalen, Els
Francke, Christof
Hughes, Samantha
A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title_full A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title_fullStr A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title_full_unstemmed A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title_short A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
title_sort new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated caenorhabditis elegans screening platform
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399480/
https://www.ncbi.nlm.nih.gov/pubmed/36033279
http://dx.doi.org/10.1016/j.heliyon.2022.e10108
work_keys_str_mv AT haerkensfreek anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT kikkencharlotte anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT kirkelslaurens anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT vanamstelmonique anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT wouterswillemijn anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT vandoornmalenels anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT franckechristof anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT hughessamantha anewuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT haerkensfreek newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT kikkencharlotte newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT kirkelslaurens newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT vanamstelmonique newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT wouterswillemijn newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT vandoornmalenels newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT franckechristof newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform
AT hughessamantha newuseforolddrugsidentifyingcompoundswithanantiobesityeffectusingahighthroughputsemiautomatedcaenorhabditiselegansscreeningplatform